European Parliament

2014-2019



Plenary sitting

B8-0116/2017

11.1.2017

MOTION FOR A RESOLUTION

pursuant to Rule 133 of the Rules of Procedure on the rhinopharyngitis vaccine

Mireille D'Ornano

RE\1114730EN.docx PE598.424v01-00

B8-0116/2017

Motion for a European Parliament resolution on the rhinopharyngitis vaccine

The European Parliament,

- having regard to Article 168 of the Treaty on the Functioning of the European Union,
- having regard to Rule 133 of its Rules of Procedure,
- A. whereas the cold is a respiratory infection affecting the whole population in the United States, an adult suffers from an average of two to four episodes per year which is generally a minor infection but can result in substantial economic loss, in particular due to the consequent days of work absence;
- B. whereas, according to the University of Vienna, a rhinovirus vaccine could be developed based on initial research and a patent application has already been filed;
- C. whereas, according to the person leading the abovementioned research, the vaccine could be developed and distributed within six to eight years, subject to the availability of funding for further research;
- 1. Encourages the Commission to support research into a rhinopharyngitis vaccine, and in particular the abovementioned research.

